Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

3 June 2004

journal article
clinical trial
Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging

Vol. 31 (10) , 1386-1392
https://doi.org/10.1007/s00259-004-1561-6

Abstract

For the internal radiotherapy of neuroendocrine tumours, the somatostatin analogue DOTATOC labelled with ⁹⁰Y is frequently used [⁹⁰Y-DOTA-Phe¹-Tyr³-octreotide (SMT487-OctreoTher)]. Radiation exposure to the kidneys is critical in this therapy as it may result in renal failure. The aim of this study was to compare cumulative organ and tumour doses based upon dosimetric data acquired with the chemically identical ⁸⁶Y-DOTA-Phe¹-Tyr³-octreotide (considered as the gold standard) and the commercially available ¹¹¹In-pentetreotide.

Keywords

This publication has 17 references indexed in Scilit:

86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
European Journal of Nuclear Medicine and Molecular Imaging, 2003
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
2002
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide
European Journal of Nuclear Medicine and Molecular Imaging, 2001
End-stage renal disease after treatment with 90 Y-DOTATOC
European Journal of Nuclear Medicine and Molecular Imaging, 2001
A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy
American Journal of Kidney Diseases, 2001
Peptide receptor imaging and therapy.
2000
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
European Journal of Nuclear Medicine and Molecular Imaging, 1999
Calculation of residence times and radiation doses using the standard PC software Excel.
European Journal of Nuclear Medicine and Molecular Imaging, 1997
Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.
1993
Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
1993